IVDR Scope and Risk Classes

In vitro diagnostic products are the branch of the medical device world subject to their own separate regulation: every product producing diagnostic information from a human sample, from reagents to software and from analysers to calibrators, enters this frame. Türkiye applies the European regulation on in vitro diagnostic devices nationally; the rules on scope, classification and conformity assessment come from there. The IVDR frame's most visible feature is its risk-based class structure: products are ranked A to D by the nature of the risk they carry, and the class determines the entire regulatory load, from the notified body's role to the clinical evidence expectation. A wrong class decision invalidates the whole conformity chain, as on the device side. This article explains where the scope begins, how the classification rules are read, what the classes change, and the reflections on the import side.

Who is this for?

This guide is for every role designing, supplying, importing and using IVD products. Manufacturer representatives are the primary owner of the scope and class decision. Distributors and importers must know the class distribution in their portfolio, because the class is the leading indicator of document demands and audit risk. Regulatory teams translate the classification rules into product files. Quality units tie class changes into change management. Clinical laboratories must be aware of the class difference of the products they use; the performance monitoring obligations of high-class products reflect onto the user too. Clinical research teams track the separate permit regime of performance evaluation studies. Customs brokers carry the class information into the document set. Procurement questions the class and document consistency of products from new suppliers. At audit the question is: this product, in which class, by which rule, through which conformity route, is in the country?

Which products does it cover?

The scope includes the whole diagnostic product family: reagents, kits, calibrators, control materials, sample transport and storage tubes when used diagnostically; analysers and automated systems; software producing diagnostic decisions; auxiliary solutions such as buffers and diluents when they sit in the diagnostic chain. Companion diagnostics, tests serving the selection of a medicine's use, carry particular importance. Self-test products are kits applied by the user at home and sit high in the class structure. Plant, food and environmental tests are outside the scope as long as they do not serve human diagnosis. Veterinary diagnostic products fall under a separate regulation. Research-purpose products stay outside the scope as long as they carry no diagnostic claim; that boundary is treated separately in this series' classification article. On the GTİP side, diagnostic reagents and kits gather in a distinct position family of the tariff schedule; classification is reasoned after the status decision is given.

When does it apply?

Scope and class assessment engage on several triggers. When a new product is prepared for market, the scope test and class decision are the first step. When an existing product's intended-use declaration changes, for instance a new disease area is added or the sample type widens, the class is re-read. Software updates affect classification if they change the nature of the diagnostic output. If a companion diagnostic function is added later, the class rises visibly. A design change enabling the sample to be taken by the user triggers the self-testing provisions. Marketing language is the silent trigger of entering and leaving scope; a brochure adding a diagnostic claim pulls the product into scope. At import inspection the match between the class information and the technical file is checked. In market surveillance, performance complaints become the real test of the class risk. The rule is simple: when the claim, the sample or the intended use changes, the class is discussed.

Legal framework and authority

The frame is the European in vitro diagnostic regulation Türkiye applies nationally. The regulation defines scope through diagnostic use; binds classification to seven rules; and determines the conformity assessment route for each class. The logic of the rules is risk-focused: the consequence for individual and public health of a wrong or late diagnostic result is the class's determinant. The detection of the high-risk group of infectious agents, blood and tissue safety screening and companion diagnostics form the regulation's strict part. The competent authority is TİTCK: it applies the legislation, runs registration processes, performs market surveillance and tracks performance complaints. Notified bodies are party to conformity assessment for class B and above. On the import side inspection runs within the product safety communiqués and the Import Regime Decision. The regulation's current text, classification guides and reference lists must be tracked from official sources; rule interpretations are clarified over time through guidance.

Step-by-step process

1. Build the product's definition: reagent, instrument, software or system; write the sample type and the diagnostic information produced.
2. Run the scope test: does the product serve the diagnostic examination of human-derived samples; file the rationale.
3. Read the seven rules systematically: enter into a table the aspects of each rule that apply and do not apply to your product.
4. Determine the highest-risk applicable rule; on a rule conflict the higher class governs.
5. Put the class decision in writing: rule, rationale, date and approving signature.
6. Plan the class-driven conformity assessment route: notified body requirement and performance evidence expectation.
7. Prepare technical documentation at the depth appropriate to the class; the performance evaluation report grows heavier with class.
8. Complete registration and labelling requirements; set up the CE-IVD marking and national registration chain.
9. Tie the class information and evidence into the import document set.
10. Define the change triggers: when the claim, sample or software changes, the class is re-assessed.

Document checklist

• Product definition card: components, sample type, diagnostic output.
• Scope test rationale and the manufacturer's intended use declaration.
• Classification rule table: applied and eliminated rules.
• Class decision form: decision, rule, rationale, signature.
• Notified body process records, where required.
• Performance evaluation report and the analytical/clinical evidence summary.
• Technical documentation index, with class-appropriate content.
• CE-IVD declaration of conformity and certificate information.
• National registration outputs and representative designations.
• Label and instruction samples; with the mandatory information.

Parties and responsibilities

The chain's most question-producing link is performance evidence: the higher the class, the more systematically the monitoring of use data and complaints must be built. Monitoring on the user side is the invisible half of the importer's risk management.

Exceptions and edge cases

The edges of IVDR practice must be well known. Companion diagnostics sit at the intersection of device and medicinal legislation; agreements made with the drug developer do not change the test's status but condition its clinical use. The self-test boundary looks at who takes the sample and who interprets the result: kits leaving interpretation to the user are assessed in the high class. In genetic testing, the scope of hereditary risk information is the main factor raising the class. The distinction between near-patient testing and laboratory testing shows the class effect of the use environment. Whether the software is a standalone product or a system component changes the registration and declaration chain. The later move of products brought for scientific use into diagnostic use counts as entering scope and requires conformity assessment. Plant or veterinary equivalents stay outside the scope as long as they do not serve human diagnosis. If a product set contains components in different classes, the set as a whole and the components are assessed separately. In every borderline case the basis is written: the rule text, the guidance or the authority's opinion.

Common mistakes

The most common mistake is gathering all reagents into class A; if the intended use triggers the high-class rules, the decision is wrong. The second is giving the class decision from old-regulation habit; the frame has changed and the rules have tightened. The third is dropping the companion diagnostic function from the file; this function raises the class directly. The fourth is seeing the self-test feature as a marketing advantage and missing the class effect. The fifth is leaving the software component outside scope; software producing diagnostic decisions is a product. The sixth is not filing the class rationale; the decision exists, its basis does not, and it collapses at audit. The seventh is not tying class changes into change management; the class stays old as the product develops.

Important notice

This article is general information, not legal or customs advice; for a product's scope and class, the applicable legislation, classification guides and where necessary the competent authority's opinion must govern. GTİP codes and class examples in the text are for orientation; the GTİP examples are not binding. Legislation and guides can be updated; official sources must be checked before any transaction.